|
|
|
|
Product Candidates OverviewPipelineOrphan Drug Designations

Pipeline

USA

Product Candidate   Indication   Development Stage
Ampligen®   CFS/ME   NDA Active. Company in discussions with FDA to formulate path forward for potential approval
     
Ampligen®   CFS/ME   Treatment Protocol - Active
     
Ampligen®   Ovarian Cancer   Phase I/II - Sponsored by University of Pittsburgh
     
Ampligen®   Peritoneal Cancer   Phase I/II – Sponsored by University of Pittsburgh
     
Ampligen®   Colorectal Cancer   Phase II – Sponsored by University of Pittsburgh
Site Map | Privacy | Terms Of Use Copyright ©2016 Hemispherx Biopharma, Inc. | All Rights Reserved.